Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 7, 2003, Pages 486-495

  Monbaliu, Johan ^a   Verhaeghe, Tom ^a   Willems, Bart ^a   Bode, Wilhelmina ^a   Lavrijsen, Karel ^a   Meuldermans, Willem ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; CAS 1953 04 4; Cholinesterase inhibitor; Galantamine, absorption, animal pharmacokinetics, bioavailability; Reminyl

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; MALE; NONHUMAN; RAT; SEX DIFFERENCE;

EID: 0042167242     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297138     Document Type: Article

References (9)

1. Schuh, F. T., Zum molekularen Wirkungsmechanismus von Galanthamin, einem Curare-Antagonisten. Anästhesist 25, 444 (1979)
2. Thomsen, T., Bickel, U., Fischer, J. P. et al., Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1, 46 (1990)
3. Maelicke, A., Samochocki, M., Jostock, R. et al., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiat. 49, 279 (2001)
4. Raskind, M. A., Peskind, E. R., Wessel, T. et al., Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54, 2261 (2000)
5. Tariot, P. N., Solomon, P. R., Morris, J. C. et al., A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54, 2269 (2000)
6. Wilcock, G. K., Lilienfield, S., Gaens, E., Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br. Med. J. 321, 1445 (2000)
7. Wilkinson, D., Murray, J., Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Galantamine Research Group. Int. J. Geriat. Psychiat. 16, 852 (2001)
8. Gibaldi, M., Perrier, D., Pharmacokinetics, pp. 199-219. Marcel Dekker, New York-Basel (1982)
9. Summary of Product Characteristics of Reminyl® tablets, Janssen Pharmaceutica, Beerse (2000)